1. Executive Summary (Confidence: High)

Trilliome is a high-growth startup at the intersection of microbiome science and longevity medicine. Founded in 2023 in Zürich by Patrick Guye and Tim Mak, the organization aims to revolutionize the nutraceutical market by providing "pharmaceutical-grade" scientific validation for everyday food and supplement products.^[12] The organization's mission is rooted in the "Food as Medicine" philosophy, specifically addressing how modern lifestyles and sterile environments have depleted essential gut microbes critical for producing anti-inflammatory and neuroprotective metabolites.^[29]

Leveraging a proprietary AI discovery engine and advanced human gut models, Trilliome identifies precise molecular combinations from plant-based sources to restore "keystone" microbial species.^[29] Its lead bioactive product, TRI-01, has demonstrated significant neuroprotective and immune-balancing properties in human-relevant ex-vivo studies.^[12] Backed by seed funding and recognized with multiple industry awards, Trilliome is transitioning toward clinical validation and global B2B partnerships with supplement and functional food brands.^[12]